Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab - A Randomized, Double-blind, Placebo-controlled, Non-comparative Phase II Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07387198

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:29:08.168814+00:00

Published At

2026-04-17T00:00:00+00:00

Record Updated At

2026-04-17

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Merkel Cell Carcinoma, Stage I", "Merkel Cell Carcinoma, Stage II", "Neoadjuvant Immunotherapy"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-04-17"

protocolSection.identificationModule.nctId

"NCT07387198"

protocolSection.identificationModule.officialTitle

"Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab - A Randomized, Double-blind, Placebo-controlled, Non-comparative Phase II Study"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Merkel Cell Carcinoma, Stage I (protocolSection.conditionsModule.conditions)
• Merkel Cell Carcinoma, Stage II (protocolSection.conditionsModule.conditions)
• Neoadjuvant Immunotherapy (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.